Singapore markets close in 6 hours 4 minutes

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.1900+0.0300 (+2.59%)
At close: 04:00PM EDT
1.1800 -0.01 (-0.84%)
After hours: 07:53PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 167.60M
Enterprise value 741.40M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)1.10
Price/book (mrq)N/A
Enterprise value/revenue 5.29
Enterprise value/EBITDA -3.34

Trading information

Stock price history

Beta (5Y monthly) 0.53
52-week change 3-72.20%
S&P500 52-week change 3-16.62%
52-week high 34.7600
52-week low 30.5800
50-day moving average 31.3516
200-day moving average 31.7420

Share statistics

Avg vol (3-month) 36.66M
Avg vol (10-day) 32.15M
Shares outstanding 5144.48M
Implied shares outstanding 6N/A
Float 8142.41M
% held by insiders 11.44%
% held by institutions 130.65%
Shares short (14 Sept 2022) 433.16M
Short ratio (14 Sept 2022) 48.03
Short % of float (14 Sept 2022) 423.40%
Short % of shares outstanding (14 Sept 2022) 422.95%
Shares short (prior month 14 Aug 2022) 429.66M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin -187.70%
Operating margin (ttm)-154.23%

Management effectiveness

Return on assets (ttm)-28.02%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)140.27M
Revenue per share (ttm)1.05
Quarterly revenue growth (yoy)-12.70%
Gross profit (ttm)115.3M
EBITDA -208.5M
Net income avi to common (ttm)-263.3M
Diluted EPS (ttm)-2.0840
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)94.58M
Total cash per share (mrq)0.65
Total debt (mrq)668.38M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.17
Book value per share (mrq)-2.55

Cash flow statement

Operating cash flow (ttm)-181.03M
Levered free cash flow (ttm)-116.45M